COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC

November 03, 2023



« back to news page